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AbstrACt
Introduction Mental health interventions delivered through 
digital technology have potential applications in promoting 
recovery and improving outcomes among people in the 
early stages of psychosis. Self-management approaches are 
recommended for the treatment of psychosis and could be 
delivered via applications (apps) installed on Smartphones 
to provide low-cost accessible support. We describe the 
protocol for a feasibility trial investigating a self-management 
Smartphone app intervention for adults using Early Intervention 
in Psychosis (EIP) services.
Methods and analysis In this feasibility randomised 
controlled trial, 40 participants will be recruited from EIP 
services in London and Surrey. Twenty participants will 
be randomised to receive a supported self-management 
Smartphone app (My Journey 3) plus Treatment As Usual 
(TAU), while the other 20 participants will receive TAU only. The 
primary objective of this study is to evaluate the feasibility of 
conducting a full-scale trial of this intervention in EIP services. 
Participant data will be collected at baseline and at two follow-
up assessments conducted 4 months and 12 months post-
baseline. Analysed outcome measures will include relapse 
of psychosis (operationalised as admission to a hospital or 
community acute alternative), mental health and well-being, 
recovery, quality of life and psychopathology. Semi-structured 
interviews with participants and EIP service clinicians will 
additionally explore experiences of using My Journey 3 and 
participating in the trial and suggestions for improving the 
intervention.
Ethics and dissemination The App to support Recovery 
in Early Intervention Services study has been reviewed 
and approved by the National Research Ethics Service 
Committee London—Brent (Research Ethics Committee 
reference: 15/LO/1453). The findings of this study will be 
disseminated through peer-reviewed scientific journals 
and conferences, magazines and web publications.
trial registration number ISRCTN10004994.
IntroduCtIon 
Psychosis is associated with significant 
costs at individual-level, family-level and 
society-level.1–3 The implementation of Early 
Intervention in Psychosis (EIP) services across 
the UK has been associated with improved 
outcomes,4 5 however, substantial challenges 
remain. Long-term follow-up studies have 
shown that relapse rates in the early course 
of psychosis remain high.6 Furthermore func-
tional recovery is often not attained following 
treatment.7 
Thus, there is a need to increase and 
sustain benefits from EIP services. An 
approach with demonstrated efficacy in 
improving functional recovery and reducing 
relapse in psychosis is supported self-manage-
ment.8 Self-management has been designed 
to empower people as active agents in their 
own recovery by enabling them to develop 
skills such as recognising and monitoring 
strengths and limitations of this study
 ► The app has been well developed prior to the fea-
sibility trial, including substantial stakeholder input 
to the development of the intervention at all stages, 
an initial period of testing in clinical settings, and 
refinement of the current version through lab and 
field testing.
 ► The acceptability and feasibility of the intervention 
and the study design of a future full-scale trial will 
be explored using a variety of measures, including 
recruitment and retention rates, usage data, and 
qualitative interviews on experience of use.
 ► The trial will only recruit Android Smartphone users 
as My Journey 3 is not as yet compatible with other 
Smartphone operating systems; this will limit sam-
ple representativeness.
 ► This is a feasibility study, thus not powered to draw 
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symptoms and early warning signs of relapse, identifying 
and avoiding stressors, and using effective coping strat-
egies.9 Self-management is associated with significant 
benefits including reduced distress, improved medication 
adherence and reduced number of hospitalisations.10–12 
Relapse prevention work has long been proposed as a key 
element in EIP,13 and establishing and working towards 
recovery goals is widely advocated in EIP services.14 
However, well-evaluated tools and methods are currently 
not available to support widespread implementation of 
self-management approaches in EIP services.
Over recent years there has been growing interest in the 
development of innovative technologies in healthcare due 
to their potential to improve accessibility, efficacy, quality 
and cost-effectiveness of treatment.15 Due to rapid advance-
ments in mobile phone technology, it is possible to deliver 
clinical interventions via applications (apps) installed on 
Smartphones (mobile phones with computational capaci-
ties). Smartphones are widely available in the UK with over 
75% of adults owning one.16 They are often carried on the 
person with high accessibility to the internet and are there-
fore a suitable device to provide time-unlimited interven-
tions in almost any location.17
Recent evidence suggests that people with psychosis are 
adopting digital technology in a similar way to the general 
population,18–20 and that they are interested in using 
mental health interventions delivered via Smartphones.21 22 
A systematic review has found that interventions delivered 
through apps or text messaging on Smartphones are 
acceptable and feasible for people with psychosis and may 
support recovery.23 Smartphone apps based on self-man-
agement principles have shown promise in a wide range of 
long-term health conditions,24 and are a potential way to 
deliver accessible low-cost support to adults with psychosis.
Although emerging research suggests that Smartphone 
apps hold promise in delivering effective interventions 
to adults with psychosis, the evidence base is under-devel-
oped in comparison to more common mental disorders.25 
To date only one randomised controlled trial (RCT) of a 
psychosocial Smartphone app used in EIP services has 
been published.26 In this proof-of-concept trial, 36 adults 
accessing EIP services were randomised to use a cogni-
tive-behavioural therapy informed Smartphone app (Actis-
sist) that aims to encourage active self-management, or a 
symptom-monitoring app which was classed as the control 
condition. Actissist was found to be acceptable, feasible and 
safe for adults accessing EIP services. Although not powered 
to find an effect, the study suggests that Actissist may confer 
benefits to users’ outcomes over and above a passive symp-
tom-monitoring app. Participants however only had access 
to the app for 12 weeks, were followed-up over a relatively 
short time frame (22 weeks) and significant mental health 
outcomes such as relapse were not measured. This work has 
been conducted in parallel with our study, and we antic-
ipate both programmes of work will contribute to devel-
oping an evidence base as to whether Smartphone apps 
that promote self-management can improve outcomes in 
first-episode psychosis and reduce healthcare costs.
Aims and objectives
The aim of the App to support Recovery in Early Interven-
tion Services study is to examine the feasibility of conducting 
a full-scale trial of a clinician supported self-management 
Smartphone app for adults accessing EIP services. The 
feasibility trial will aim:
1. To identify whether a self-management Smartphone 
app is acceptable to use and feasible to support in EIP 
services in the context of a research study, and to iden-
tify any necessary modifications to the intervention 
content and design, or to its delivery in EIP services.
2. To test the feasibility and acceptability of trial proce-
dures for a definitive trial.
3. To test procedures for evaluating intervention engage-
ment and participant outcomes.
MEthods And AnAlysIs
design
The study is a feasibility RCT comparing a clinician 
supported self-management Smartphone app (My Journey 
3), in addition to Treatment As Usual (TAU), to a control 
group receiving TAU only. The design as described here 
adheres to the Standard Protocol Items: Recommendations 
for Interventional Trials (SPIRIT).27 A copy of the SPIRIT 
checklist is provided as online supplementary file 1. Rele-
vant items from the WHO Trial Registration Data Set are 
detailed in online supplementary file 2.
setting
The trial will take place in six EIP services across three 
National Health Service (NHS) Foundation Trusts in 
England: Camden and Islington; East London; and Surrey 
and Borders Partnership. All participating EIP services 
provide care co-ordination to service users, access to a 
psychiatrist and psychiatric medication and psychosocial 
interventions, aiming to conform to the current UK model 
for EIP services.28 None of the participating EIP services 
offer Smartphone apps or any other digital interventions 
as part of routine care, nor are structured self-management 
tools consistently available in these teams. A list of partici-
pating sites is available from the authors.
Participants
Forty service users will be recruited from the participating 
EIP services. Assuming a conservative estimate of a 40% 
attrition rate, the study should feature 12 completer partic-
ipants in each group as recommended for feasibility and 
pilot trials.29 The proposed sample size will therefore be 
sufficient to establish the acceptability of My Journey 3 and 
the feasibility of trial procedures.
Eligibility criteria
Inclusion criteria
 ► Aged 16 or older.
 ► Have experienced at least one episode of psychosis.
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 ► User of a Smartphone with an Android operating 
system.
Exclusion criteria
 ► Lack of capacity to provide informed consent to 
participate in the trial.
 ► Inability to communicate and understand English 
sufficiently to understand trial procedures and use My 
Journey 3.
 ► In the view of their EIP service, poses such a high risk 
to others that it would be unsafe to conduct research 
meetings even on NHS premises.
Criteria are deliberately broad in order to reach conclu-
sions generalisable to a wide range of EIP service users. 
Due to limited resources My Journey 3 has been devel-
oped for one Smartphone operating system (Android) 
at this stage of testing. Nearly half of Smartphones used 
in the UK use Android operating systems.16 There is also 
emerging evidence that Android may be the Smartphone 
operating system most often used by adults with severe 
mental illness.21 Resources are not currently available to 
deliver My Journey 3 in languages other than English.
recruitment
An overview of the recruitment procedure is displayed in 
the flow diagram (figure 1). Clinicians will identify EIP 
service users who appear potentially eligible for the trial. 
They will then make initial contact, explain the trial and 
ask if the potential participant is willing to be contacted 
by a researcher. If a potential participant is eligible and 
interested in taking part, a researcher will contact them 
to further explain the trial and to arrange a face-to-face 
meeting. At this meeting the researcher will provide the 
trial information sheet, confirm eligibility, invite any 
questions about participating and assess the service user’s 
capacity to provide informed consent. Written consent to 
participate will be obtained using a consent form (online 
supplementary file 3) prior to undertaking the baseline 
assessment at the same meeting. Participants will be noti-
fied that they will be free to withdraw from the study at 
any time-point. Prior to study recruitment, researchers 
will undertake training in how to assess mental capacity 
and take informed consent.
To minimise loss to follow-up, participants will be 
asked to give their preferred contact details, and for their 
permission for the researcher to contact a nominated 
close other or EIP service clinician whom could contact 
the participant if the researcher is unable to contact the 
participant directly.
randomisation
At a separate time-point following the baseline assess-
ment meeting participants will be randomly allocated in 
a 1:1 ratio to an intervention group where they will have 
access to My Journey 3 during the trial (n=20) or to a 
Figure 1 SPIRIT flow diagram outlining the phases of the App to support Recovery in Early Intervention Services feasibility 
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control group (n=20). Randomisation will be conducted 
by an independent statistician. The allocation sequence 
will be concealed from the researcher, who will be blind 
when recruiting participants and conducting baseline 
assessments. An independent researcher will hold on to 
the allocation list and disclose participants’ allocation to 
the trial researcher after the completion of the baseline 
assessments. Participants will then be informed of their 
allocation by the trial researcher. Participants cannot 
be blinded to their group allocation given the nature 
of the trial intervention and control group. As a single 
researcher will carry out most of the data collection, it is 
not practical for the group allocation of participants to be 
concealed from the research team in this feasibility study.
the intervention
Development
My Journey 3 has been developed through a series of 
iterations. The first version of My Journey was designed 
by Surrey and Borders Partnership NHS Foundation 
Trust (led by Sarah Amani), after local EIP service users 
consulted about their care suggested there would be 
significant benefits from a Smartphone app that could 
be used for appointment and medication reminders, to 
track their mood and to share their recovery progress 
with EIP staff or carers. In 2011 a project group consisting 
of EIP service users, NHS clinicians, a pharmacist and an 
NHS manager was formed to drive the development of 
the My Journey app. The following year a prototype of 
My Journey was tested by 20 EIP service users to further 
inform development of the app. Since April 2013 this 
version of My Journey has been available for download 
from Google Play (the official app store for Android 
Smartphones).
The original version of My Journey contains generic 
advice on what to do if certain clinical difficulties arise, 
but does not allow personalised relapse prevention plan-
ning or recovery goal tracking. User feedback suggested 
that this was a limitation. In the current study we have 
collaborated with digital health experts, EIP service clini-
cians and adults with lived experience of psychosis to 
adapt existing paper-and-pen self-management interven-
tion components—in routine use in NHS services—to be 
suitable for delivery in an app format.30 31 In creating the 
product specification of My Journey 3 we have incorpo-
rated these self-management components with functions 
from the original My Journey. Technical development of 
My Journey 3 has been led by MyOxygen (https:// myox-
ygen. uk/), a private app development company based in 
the UK.
Following the initial development of My Journey 3, it 
has been refined in response to two phases of prelimi-
nary testing. In the first phase six volunteer EIP services 
users participated in usability lab tests with My Journey 
3 on their own Android Smartphone. Usability testing 
featured ‘think aloud’ tests where participants completed 
set tasks using My Journey 3 while providing a contin-
uous commentary on their thoughts. This method was 
used to highlight design and usability issues and users’ 
immediate reactions to the app. Individual interviews 
were also conducted to explore participants’ perceptions 
of the ease of use of My Journey 3, concerns they might 
have and suggestions for improvements. My Journey 3 was 
modified to reflect the findings at this stage.
In the second phase a further six volunteer service 
users trialled My Journey 3 on their own Android Smart-
phone during a 1-month field study, with EIP service clini-
cians asked to support their clients’ use of the app during 
routine appointments. Following the field study, indi-
vidual interviews were conducted with service user partic-
ipants to explore how they used My Journey 3 and how it 
could be improved. Further interviews with EIP service 
clinicians explored their experience of supporting their 
client with My Journey 3. Based on these findings My 
Journey 3 was updated again prior to the feasibility trial.
Intervention outline
My Journey 3 is a Smartphone app that has been designed 
to be used alongside EIP service care and with the support 
of clinicians. My Journey 3 aims to develop and support 
users’ illness self-management skills to help facilitate 
recovery from first-episode psychosis. The My Journey 3 
home screen can be seen in figure 2.
Three main components of My Journey 3 have been 
directly taken from the original app and updated. Infor-
mation regarding psychosis, mental health and mental 
health services is provided in My Journey 3 through 
links to relevant NHS and voluntary sector websites and 
through videos of personal recovery stories. To facilitate 
symptom recognition and monitoring My Journey 3 also 
features a self-monitoring tool and symptom tracker 
where users can monitor 14 different symptoms and 
three lifestyle behaviours. Advice to help manage symp-
toms is provided after completing the symptom tracker, 
and a graphical summary of symptom severity over time 
is displayed. Users also have access to a pill tracker where 
they can log whether they have taken their psychiatric 
medication. The pill tracker features a daily alert at a 
pre-set time to remind users to input if they have taken 
their medication.
In designing My Journey 3 we have also drawn on 
evidenced-based self-management interventions to add 
structured intervention components focused on recovery 
planning and relapse prevention.30 31 These additions 
allow for users to interactively:
 ► Identify strategies and coping resources that they find 
useful in maintaining well-being.
 ► Set and track progress towards personal recovery 
goals.
 ► Identify personal early warning signs of relapse and 
strategies and coping mechanisms to put in place 
should they experience these.
 ► Create a ‘relapse plan’, an action plan to follow in 
times of crisis in order to avoid or attenuate relapse.
My Journey 3 has been designed to be used by EIP 
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can input relevant information to sections such as the 
relapse prevention plans and, with training, can provide 
assistance with the app. It is also suitable for independent 
use: the developers’ aspiration is for the app to be initially 
used in collaboration with clinicians, but for it then to 
support users’ self-management following discharge from 
EIP services.
My Journey 3 features weekly discrete notifications that 
appear on the users’ Smartphone interface to encourage 
engagement with the app. Users also have the opportu-
nity to set activity reminders that notify the user to engage 
in coping strategies and take part in pre-identified activi-
ties to promote well-being.
My Journey 3 also features a sharing functionality for 
users who wish to share their data with clinicians, family 
members, friends or other trusted third parties. This uses 
built-in sharing functionality of the user’s Smartphone, 
such as e-mail. Participants will have control of who they 
choose to share their data with at all times.
Delivery of the intervention
Each participant in the intervention group will take part 
in an individual training session with their supporting 
EIP service clinician and a researcher within 6 weeks of 
the initial consent meeting. During each training session 
participants will download My Journey 3 on to their 
Smartphone. The researcher will then give a demonstra-
tion of the app and its main functions. Participants will 
have the opportunity to practice using My Journey 3 and 
to ask questions. To facilitate use during the trial partici-
pants will be asked to input appropriate information in to 
the main functions of My Journey 3.
Participants will have access to My Journey 3 from the 
training session till the 12-month time-point. Participants 
in the intervention group will be free to withdraw from 
using My Journey 3, or decline the installation of it on 
to their Smartphone, without any impact on their study 
participation or their clinical care.
In line with evidence that clinician involvement 
increases user engagement with Smartphone apps,32 
participants’ main contact for help with using My Journey 
3 and the various intervention components will be their 
supporting EIP service clinician. Supporting EIP service 
clinicians will be encouraged by the researcher to discuss 
recovery goals and relapse prevention plans with study 
participants in routine appointments and then to assist 
participants in inputting them into My Journey 3. Clini-
cians will also be encouraged to regularly check with 
participants if they have been using My Journey 3 and if 
they need any further support with it. Clinician support 
will not be manualised. If supporting clinicians leave the 
participants’ EIP service the researcher will arrange a 
meeting to introduce any new clinicians that have clients 
using My Journey 3, to the intervention and how they 
can support service users that have access to the app. 
Researcher support with My Journey 3 will be limited to 
the initial installation and technical support as needed 
during the trial period.
The research team will have no responsibility for 
providing clinical care if any My Journey 3 data shared 
by a participant to a third party indicates a decline in 
their mental health. If any major concerns regarding 
participants’ well-being such as suicidality arise from My 
Journey 3 data shared by a participant to the researcher, 
this would be communicated to the EIP service or other 
appropriate mental health services. Third parties such as 
EIP service clinicians and carers will not be briefed by the 
research team on how to respond to such information but 
would be expected to act as appropriate in such event. 
Participants will be informed at the training session that 
any data that may suggest a decline in their mental state 
that they have shared with EIP service clinicians or carers 
may be acted on accordingly, but that My Journey 3 is not 
suitable for seeking urgent medical care while in crisis.
Control group
Participants in the control group (n=20) will receive TAU 
that will be unaffected by their participation.
Figure 2 The My Journey 3 home screen, which is seen by 
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treatment As usual
TAU for service users attending EIP services typically 
involves regular meeting with a care co-ordinator, support 
from multi-disciplinary clinicians and access to a psychia-
trist, psychiatric medication and a range of psychological 
interventions.
data collection
The participant timeline is summarised in table 1. 
All participants will be asked to complete self-report 
questionnaires during a structured assessment with 
a researcher at three time points: baseline (prior to 
randomisation), 4 months post baseline and 12 months 
post baseline. Participants in the intervention group will 
also be invited to complete an audio-recorded interview 
with a researcher during the 4-month follow-up assess-
ments. Before arranging each assessment, the researcher 
will check with any clinicians in contact with the service 
users that the participant does not pose a risk to others 
and himself/herself and that it would be safe to conduct a 
research meeting. If there is an identified risk too serious 
for a meeting on NHS premises the participant will not be 
met for the assessment at that time-point, with the reason 
Table 1 Timeline of participant enrolment, interventions, assessments and patient records data collection








  Eligibility screen X
  Informed consent X
  Randomisation X
Intervention
  My Journey 3 (intervention group)
  TAU (all participants)
Assessments
  PANSS X X X
  Socio-demographic information X X X
  Clinical service use X X X
  Social Outcomes Index X X X
  Mental Health Confidence Scale X X X
  The Process of Recovery Questionnaire X X X
  WEMWBS X X X
  The DIALOG Scale X X X
  Service Engagement Scale (completed by EIP 
service clinicians)
X X
  Qualitative interviews (with participants in the 
intervention group and supporting clinicians)
X
Patient records data (from previous 12 months to 
time point)
  Number of admissions to acute mental health 
services
X X
  Number of compulsory admissions to acute 
mental health services
X X
  Total number of days in acute care X X
  Number of kept appointments with community 
mental health services
X X
  Number of missed appointments with 
community mental health services
X X
  Primary ICD-10 diagnosis X X
  Most recent care cluster X X
  Care Programme Approach status X X
*Participants in the intervention group only.
EIP, Early Intervention in Psychosis; ICD-10, Internal Classification of Diseases: 10th Revision; MJ3, My Journey 3; WEMWBS, 
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for not arranging a meeting documented. If any major 
concerns regarding participants’ risk or well-being arise 
during interactions with the researcher, this would be 
communicated to the appropriate EIP service.
Prior to the completion of each assessment participants 
will be provided with a trial information sheet. Their 
capacity to give informed consent will be assessed and 
their consent documented in writing. Participants will 
receive 20 pounds as a token of thanks for completing 
each assessment. Participants that have been discharged 
from EIP services during the trial will still be invited to 
attend assessments.
Once the recruitment target for the study has been met, 
the researcher will contact the appropriate administrators 
or informatics team within each NHS trust to arrange the 
collection of participant data from patient records. The 
researcher will also arrange for data to be collected from 
patient records 1 year later.
To test procedures for evaluating engagement with the 
intervention, data regarding My Journey 3 use will be 
collected throughout the trial period for all participants 
in the intervention group. My Journey 3 will automatically 
upload encrypted usage data to a secure trial server when 
the user has internet access on their Smartphone.
Measures
Data from patient records
The following data will be collected from patient records 
at baseline and the 12-month time-point:
a. Most recent clinical diagnosis as recorded in patient 
records using the Internal Classification of Diseases: 
10th Revision classification.
b. Most recent care cluster (a classification of mental 
health service users based on their needs, used in the 
NHS).
c. Whether participants are subject to a care programme 
approach (NHS mental health services’ case manage-
ment model).
d. Service use during the previous 12 months measured 
at baseline and 12 months post study entry. Data will in-
clude history of use of acute mental health services, in-
patient admissions and compulsory admissions and the 
number of kept and missed appointments with mental 
health services. Relapse of psychosis, the proposed pri-
mary outcome for a fully powered RCT, will be opera-
tionalised as participant admission to an acute mental 
health service (inpatient psychiatric wards, crisis hous-
es, crisis resolution teams and acute day care services). 
This definition of relapse has been used previously in 
a recent trial of a self-management intervention in a 
mental health setting.33
My Journey 3 usage data
The data collected will be a record of each time the user 
opens My Journey 3, whether this was in response to a 
prompt, and which components they use. Usage data 
will not include participants’ text input or responses 
to self-rated questions, and will therefore not give any 
information regarding the mental health of users. Usage 
data will be solely used to assess the acceptability of My 
Journey 3 and user engagement with it.
Self-report questionnaires
The following are measured as potential secondary 
outcomes for a future fully-powered RCT:
Service use measures over 1 year of follow-up.
1. Engagement with EIP services as measured by the 
Service Engagement Scale (SES),34 a 14-item question-
naire that measures engagement for four different 
dimensions: availability, collaboration, help-seeking 
and treatment adherence. The SES will be complet-
ed by EIP service clinicians, such as participants’ 
care co-ordinators, at baseline and at the 12-month 
time-point.
Measures at baseline, 4-month and 12-month follow-up 
assessments.
1. Psychotic symptoms and general psychopathology, 
measured by the Positive and Negative Syndrome 
Scale (PANSS), a 30-item scale that yields three sepa-
rate scores on positive symptoms, negative symptoms 
and general psychopathology.35 To inform the PANSS 
a trained researcher will conduct clinical interviews 
with participants at each assessment.
2. Social outcomes, rated by the Social Outcomes Index 
(SIX),36 a 6-item index of social outcomes and circum-
stance.
3. Mental health-related self-efficacy, measured by the 
Mental Health Confidence Scale,37 a 16-item self-re-
port scale of service users’ confidence in their ability 
to cope with stressful or difficult events.
4. Self-rated recovery measured by the Questionnaire 
about the Process of Recovery (QPR),38 a 22-item mea-
sure, yielding a total score and subscale scores for in-
trapersonal and interpersonal recovery factors.
5. Mental well-being, rated by total score on The War-
wick-Edinburgh Mental Well-Being Scale (WEM-
WBS),39 a 14-item self-report scale of mental well-be-
ing.
6. Subjective quality of life and satisfaction with treat-
ment measured by The DIALOG scale,40 an 11-item 
self-report scale.
7. Socio-demographic characteristics including age, gen-
der and ethnicity. We will also collect data regarding 
accommodation and living situation, employment sta-
tus, educational attainment and Smartphone use, in-
cluding use of other mental health apps.
Qualitative interviews
Interviews with participants in the intervention group will 
follow a topic guide and will explore their experience of 
using My Journey 3, including:
 ► The usability and acceptability of My Journey 3.
 ► Positives and negative aspects of My Journey 3.
 ► Impact of My Journey 3 on their life.
 ► Facilitators and barriers to using My Journey 3.
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 ► Views on the support they received from their clini-
cian in using My Journey 3.
EIP service clinicians who have been supporting partici-
pants with My Journey 3 will also be asked to complete an 
audio-recorded interview close to the time the participant 
completes the 4-month follow-up assessment. Written 
consent to take part will be confirmed beforehand, with 
an information sheet provided. Clinicians will be asked 
to provide demographic data prior to undertaking the 
interview. The interview will follow a topic guide and will 
focus on:
 ► Positives and negative aspects of My Journey 3.
 ► The experience of supporting clients with My Journey 
3.
 ► Facilitators and barriers to providing support and 
to the incorporation of My Journey 3 in clinical 
management.
 ► Views on the training session.
data analysis
No pre-specified criteria have been set for establishing 
the acceptability of My Journey 3 or the feasibility of 
trial procedures. The acceptability of My Journey 3 for 
EIP service users and clinicians will be determined from 
feedback given from the qualitative interviews and the 
level of participants’ My Journey 3 use indicated from 
the app usage data. Trial feasibility will be assessed from 
reviewing recruitment rates, drop-out rates and interven-
tion enrolment and use during the trial period. These will 
be reviewed by the study team and discussed with stake-
holders at a final dissemination event to decide on future 
steps to take.
Quantitative analysis
We will report rates of recruitment and retention in the 
trial, and, for the intervention group, the level of usage 
of My Journey 3 during the trial. The demographic and 
clinical characteristics of participants at baseline will 
be summarised separately for each study group using 
descriptive statistics.
To pilot the methods of analysis for a full-scale trial we 
will use an intention-to-treat approach using data from 
all randomised participants. The effect of My Journey 
3 on relapse (the proposed primary outcome for a 
fully-powered RCT) during the 12-month trial period 
will be estimated using logistic regression. The effect of 
the intervention on continuous outcome measures (SIX, 
QPR, WEMWBS, DIALOG scale, PANSS and SES) will be 
estimated using linear regression adjusting for the base-
line measure of the outcome in question. Results will be 
summarised using effect estimates and 95% CIs only. No 
interim analyses are planned.
Qualitative analysis
To assess the acceptability of My Journey 3 interview data 
with participants in the intervention group and supporting 
EIP service clinicians will be analysed based on The Theo-
retical Framework of Acceptability for healthcare system 
interventions.41 Analyses will be conducted collabora-
tively by a group of researchers.
Patient and public involvement
Independent advice will be sought from a trial steering 
group. Members will include researchers with expertise 
in developing and testing digital health interventions, 
EIP service clinicians, people with lived experience 
of first-episode psychosis and carers. Steering group 
members with lived experience of psychosis were 
consulted on the first paper prototypes of My Journey 3 
and on the research protocol. The version of My Journey 
3 tested in the current feasibility trial has been devel-
oped based on EIP service users’ feedback from the 
usability tests and field study. Participants will be offered 
a summary of the research findings at the end of the 
study.
data monitoring and management
A secure password-protected trial database will be devel-
oped and managed to store all quantitative data using 
SPSS software V.23, and will feature non-identifiable 
trial IDs only. Data entry of participants’ questionnaires 
will be primarily undertaken by the trial researcher, 
with a random sample checked by other research team 
members. Anonymised electronic interview transcripts 
will be checked for accuracy and stored using NVivo for 
Windows (QSR International Pty Ltd V.11, 2016). After 
the trial, all data will be archived securely at University 
College London.
Due to the small sample size of the study a data moni-
toring committee is not planned, but the steering group 
will advise if one is later needed.
EthICs And dIssEMInAtIon
Confidentiality
Participant data will be accessed by the research team only. 
Consent forms and data collection forms will be securely 
stored in locked cabinets at University College London. 
Data collection forms will not feature participants’ names 
but a unique trial ID that could not be linked to partic-
ipants by anyone outside the research team. Consent 
forms that identify participants will be kept separately 
from data collection forms.
Password-protected electronic data will be stored on 
the secure IT network at University College London. App 
usage data collected while using My Journey 3 will be 
anonymised and encrypted and will not contain personal 
user information.
serious adverse events
Serious adverse events such as hospital admissions and 
death reported to the trial team will be reviewed by the 
chief investigator. Identified adverse events assessed as 
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dissemination
Results will be disseminated through scientific publica-
tions, and to a wider audience via magazines and web 
publications.
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